Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder, ...
ARO-C3 is one of Arrowhead’s earliest-stage clinical candidates and is designed to target complement-mediated diseases. (Getty Images) Arrowhead Pharmaceuticals’ phase 1/2a study has found the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results